SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.

Also called NCT03050229

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 174 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03050229
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03050229. Randomized; quadruple masking; primary purpose treatment. Start 2017-01 (actual); primary completion 2017-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
Condition
Nocturnal Hypertension
Condition
T2DM (Type 2 Diabetes Mellitus)
Intervention (Drug)
Empagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Jichi Medical University (class: other)
Collaborator
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03050229
Content hash
dc57d9df85239e6b134c19e697b54ec8c182f0499ae31da435c1eaf8f581e883